Many of the toxicology services performed by Cyprotex are customized assays based on our customer’s specific requirements. We provide a flexible service where we can investigate different cell lines, endpoints and time points to address particular customer issues.
Our senior scientists work with our clients to bring together our expertise in toxicology and assay development with our customer’s project specific experience. Typically before embarking in a project we discuss the project in depth and agree on the best approach to take. As well as 2D cell culture we offer 3D cell culture models provide a system for long term dosing protocols.
The relevance of in vitro assays to clinical observations can be reliant on the relative exposure of the drug to tissues and organs. Incorporating exposure levels into the study design can build on toxicity predictions, we have found that incorporation of Cmax data (either generated experimentally or through a PBPK modeling approach) can improve the in vitro – in vivo extrapolation. We are able to use this approach on custom projects to better understand the clinical relevance of the in vitro data.
High Content Screening Approach
Although we offer a range of different analytical techniques for assessing toxicology, High Content Screening (HCS) is becoming one of the most widely used technologies in the field of toxicology and drug discovery. HCS allows cellular processes to be tracked using fluorescent dyes or fluorescently labeled antibodies. It has the advantage that multiple endpoints can be monitored in the same cell. We have worked on a wide range of end points and cells types, examples of which are detailed below and we are constantly developing and validating new protocols.
Cytotoxicity Screening Assay (cell count, nuclear size, DNA structure, mitochondrial potential, mitochondrial mass, cytochrome c and cell membrane permeability) – option to be performed +/-S9 with HepG2 cells.
Additional cell lines can be purchased on request or transferred to Cyprotex.
Custom HCS Cell Based Assays
New endpoints and multiplexed assays can be developed at Cyprotex on client demand. Also validated client in-house assays can be transferred to Cyprotex for regular screening. If suitable commercial antibodies or reagents are available for your gene of interest, a HCS assay to detect the cellular response can be developed.
Please contact us to find out more about our custom toxicology and assay development services.